The Medicinal Chemist's Guide to Solving ADMET Challenges

Early ADMET (absorption, distribution, metabolism, excretion and toxicity) profiling in small molecule drug discovery has significantly reduced later-stage failures due to inadequate pharmacokinetics and safety liabilities over the past two to three decades. A wealth of knowledge on design strategies to address common ADMET issues has been compiled in "The Medicinal Chemist’s Guide to Solving ADMET Challenges" co-authored by experts from academia and industry.

In this Flash Talk, Patrick Schnider, a seasoned medicinal chemist and the editor of this book, discusses the challenges of capturing and retrieving medicinal chemistry knowledge and how these have been addressed in the guide and answers audience questions live.

00:00 Welcome and introduction
02:33 Presentation
32:29 Key Takeaways
34:49 Q&A

Presented by Patrick Schnider, Ph.D. with hosts Dennis Hu, Ph.D., CEO and Dennis Koester, Ph.D. Director of Industry Research and Relations, Drug Hunter

For a case study where several ADME challenges were solved check out this premium article:
https://drughunters.com/ziritaxestatyt
Ziritaxestat is an oral ATX (autotaxin) inhibitor for the treatment of IPF (idiopathic pulmonary fibrosis) from Galapagos. The team successfully tackled challenges related to hERG inhibition and CYP TDI to nominate their clinical candidate. Read the case study to find out more.

Recorded on August 8, 2024, as a Drug Hunter Flash Talk.

Sign up for future sessions here: https://drughunter.com/flash-talk-ser...